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Purpose: Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is a new, broad-spectrum agent that has an inhibition effect
on the proliferation, migration, and collagen contraction of human Tenon’s fibroblasts, and thus modulating the wound
healing process of glaucoma filtering surgical site. This study investigated the pharmacokinetics of topically administered
pirfenidone (0.5%) in rabbit eyes.
Methods: Pirfenidone solution (50 μl) was instilled into the rabbit’s conjunctival sac. The rabbits were quickly sacrificed
at 2, 5, 8, 10, 15, 20, 30, 60, 90, and 120 min after the administration and ocular tissues were obtained. The concentrations
of pirfenidone in conjunctiva, sclera, cornea, aqueous humor, and vitreous were determined by high performance liquid
chromatography.
Results: After topical administration, there was wide distribution and fast clearance of pirfenidone among the various
ocular tissues. The mean maximum concentrations (Cmax) of pirfenidone in cornea, conjunctiva, sclera, aqueous humor,
and vitreous were 9.64 mg/g, 9.62 mg/g, 2.13 mg/g, 34.88 mg/l and 0.52 mg/l, respectively. The half-life for these tissues
was 18.26, 34.16, 15.71, 70.91, and 39.48 min, respectively.
Conclusions: Measurable concentrations of pirfenidone are achieved in ocular tissues after topical application in rabbit
model. Topical administration of pirfenidone may be an effective approach for modulation of wound healing responses
in glaucoma filtration surgical site.
Glaucoma  is  the  second  leading  cause  of  blindness
worldwide  [1].  Elevated  intraocular  pressure  (IOP)  is
considered as the most consistent risk factor for glaucoma
[2],  although  the  pathogenesis  of  glaucomatous  optic
neuropathy remains unclear. Glaucoma filtration surgery such
as trabeculectomy remains the mainstream of treatment [3].
Specifically, trabeculectomy offers an IOP-lowering effect by
creating  an  outflow  pathway  from  anterior  chamber  to
subconjunctival spaces [4]. One of the important reasons for
the failure of this surgery is scarring at filtering surgical site,
which could block the aqueous humor outflow [5]. To address
this problem, many anti-fibrotic products (e.g., 5-fluorouracil
and mitomycin C) have been developed [4]. However, the
administration  of  these  agents  has  been  limited  by  their
toxicity and unappreciated complications (e.g., bleb leakage,
hypotonous  maculopathy,  and  infectious  endophthalmitis)
[6-11].
Pirfenidone  (5-methyl-1-phenyl-2-[1H]-pyridone)  is  a
new and broad-spectrum agent that has anti-fibrotic and anti-
inflammatory  effect  in  organs  such  as  lung  [12,13],  liver
[14], and kidney [15]. In a recent phase III multi-national
clinical trial, pirfenidone has been shown to have beneficial
effects  for  patients  with  various  stages  of  idiopathic
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pulmonary fibrosis [16]. While the efficacy and safety of oral
pirfenidone have been established in such specific diseases,
limited data are available in its ophthalmic use.
Our group has previously shown that pirfenidone can
prevent proliferation, migration and collagen contraction of
human Tenon's fibroblasts in vitro [17]. We found that the
inhibiting roles of pirfenidone on human Tenon's fibroblasts
may be achieved by inhibiting mRNA and protein expression
of  transforming  growth  factor-β  (TGF-β)  isoforms  [17].
Furthermore,  we  demonstrated  that  postoperative
administration  of  0.5%  pirfenidone  was  associated  with
improved bleb survival in rabbit glaucoma surgery model
[18].  In  addition,  pirfenidone  has  been  shown  to  inhibit
expression of tissue inhibitors of metalloproteinases-1 and it
has anti-fibrotic effects on orbital fibroblasts from patients
with thyroid-associated ophthalmopathy [19]. These findings
warrant the potential therapeutic effects of pirfenidone for
glaucoma filtration surgery and other fibrosis-related ocular
diseases. To our knowledge, however, critical information
regarding  the  pharmacokinetics  of  pirfenidone  in  various
intraocular  tissues  has  not  been  available.  This  study
investigated the pharmacokinetics of 0.5% pirfenidone as a
topically administered solution in eyes of live rabbits.
METHODS
Animals: The study was conducted according to the ARVO
Statement for the Use of Animal in Ophthalmic and Vision
Research. The study was approved by the Welfare Committee
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2191of Animals in Zhongshan Ophthalmic Center, Guangzhou,
China. Sixty Albino rabbits, weighting 2–2.5 kg each, were
obtained  from  Medical  Laboratory  Animal  Center,
Guangdong Province. All animals were housed in clean cages
at ambient temperature, and were acclimatized for at least one
week before use.
Drug  preparations:  Pirfenidone  was  provided  by  Sigma-
Aldrich Co. (St. Louis, MO). Pirfenidone was dissolved in
sterile water to achieve a final concentration of 0.005 g/ml
(0.5%  pirfenidone).  The  solutions  were  sterilized  by  the
manufactory laboratory of Zhongshan Ophthalmic Center and
then distributed equally into 60 sterile plastic eye-drop bottles,
each assigned to one rabbit.
Apparatus  and  chromatographic  conditions:  The  high-
performance  liquid  chromatograph  (HPLC;  Shimadzu,
Kyoto, Japan) apparatus consisted of a Shimadzu LC-20AT
separation  module  and  an  SPD-20A  UV  detector  (Kyoto,
Japan). Study was performed on a Luna 5-μm C18 column
(150 mm×4.6 mm; Phenomenex, Torrance, CA). Samples
Figure 1. Chromatograms of cornea extracts. A: The chromatogram
of blank cornea. B: The chromatogram of blank cornea spiked with
pirfenidone and I.S. C: The chromatogram of cornea from the rabbit
eye treated with pirfenidone and I.S.
were eluted from the column with an acetonitrile (A)-water
(W)  mobile  phase  (with  a  programming  of  0~5  min:
35%A→65%A,  65%W→35%W;  5~5.5  min:
65%A→35%W;  5.5~8  min:  65%A→35%A,
35%W→65%W).  Sample  (20  μl)  was  injected  into  the
column for analysis with a flow rate of 1 ml/min and the UV
absorbance detector operated at 310 nm.
Preparation  of  standard  samples:  A  stock  solution  of
pirfenidone  was  prepared  and  diluted  with  methanol  to
prepare working solutions at a variety of final concentrations
(24.6, 12.3, 2.46, 1.23, and 0.62 mg/l). Working calibration
curves for conjunctiva and aqueous humor were generated by
adding a stock solution of pirfenidone to each of the blank
matrices of aqueous humor or homogenates of conjunctival
tissue.  Ethyl  4-aminobenzoate  (Sigma-Aldrich  Co.)  was
mixed with methanol and used as internal standard (IS), with
the concentration of 2.76 mg/l.
Intra-day and inter-day precision: Intra-day and inter-day (on
three different days) precision of measurement was evaluated
by analyzing vitreous sample spiked with pirfenidone at the
concentrations  of  30.75,  0.62,  and  0.077  mg/l.  At  each
concentration, there were five repeated measurements and the
precision  was  determined  by  relative  standard  deviation
(RSD).  A  RSD  <15%  was  considered  acceptable.  The
extraction  recovery  of  pirfenidone  was  measured  by
comparing the peak height of the extracted pirfenidone with
that of the un-extracted standard sample. To prepare extracted
samples, vitreous (0.1 ml) were separated and homogenized
with 0.5 ml methanol. The supernatants were extracted and
mixed with 50 μl pirfenidone and 50 μl IS. Each mixture was
centrifuged at 15,294× g for 5 min. Supernatants (20 μl) were
used as extracted samples.
Stability study: After 3 cycles of freezing and thawing within
4 h, different concentrations of pirfenidone (30.75, 0.62, and
0.077 mg/l) were stored at room temperature (25 °C) for 24
h. The stability of pirfenidone was determined by relative
error.  A  relative  error  within  ±15%  was  considered
acceptable.
Treatment protocol and tissue preparation: Sixty rabbits were
divided into ten groups with the use of a computer-assisted
evenly distributed random number list. One drop (50 μl) of
0.5% pirfenidone solution was instilled topically into one eye
of the rabbits. One group of six rabbits was sacrificed at the
following time points after the instillation of drug: 2, 5, 8, 10,
15, 20, 30, 60, 90, and 120 min. The eyes were enucleated and
the tissue samples of conjunctiva, cornea, sclera, aqueous
humor (0.1 ml) and vitreous (0.1 ml) were separated and
homogenized with 0.5 ml methanol and 50 μl IS. Each mixture
was centrifuged at 15,294× g for 5 min. The supernatants were
extracted,  evaporated  by  flowing  Nitrogen,  resolved  with
0.1ml methanol, and then centrifuged at 15,294× g for 5 min.
Supernatants (20 μl) were used for analysis.
Pharmacokinetics  analysis:  The  pharmacokinetics  of
pirfenidone in cornea, conjunctiva, sclera, aqueous humor,
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a non-compartmental model (WinNonlin Professional, ver.
5.0; Pharsight Co. Mountain View, CA). Areas under the
curve (AUC) were determined by a linear-trapezoidal method
and  the  terminal  half-life  (t1/2)  was  estimated  by  linear
regression of the concentration time points.
RESULTS
Chromatographic  separation  and  selectivity:  The
chromatograms of cornea are shown in Figure 1. Analysis on
the blank samples showed that there were no interfering peaks
in  the  chromatograms.  The  retention  time  for  pirfenidone
under the current conditions was around 4.3 min, and for
internal standard it was about 6.5 min.
Calibration  linearity:  Calibration  curves  for  assay  in
conjunctiva and aqueous humor developed with peak area
ratio  of  pirfenidone  to  internal  standard  versus  drug
concentration  were  linear  over  a  wide  range.  The  linear
regression model was Y=0.0008+1.4312X (r=0.999, ranging
from  0.02  to  6.15  mg/l)  for  conjunctiva,  and
Y=-0.0525+1.8425X  (r=0.998,  ranging  from  0.08  to
30.75 mg/l) for aqueous humor.
Intra-day and inter-day precision: At the concentrations of
30.75, 0.62, and 0.077 mg/l, the intra-day precision was 7.1,
5.5, and 8.4%, respectively, and the inter-day precision was
5.8, 3.6, and 6.9%, respectively. These results showed that the
method  was  reproducible.  For  these  concentrations,  the
extraction recoveries in aqueous humor were 97.2, 92.0, and
89.1%, respectively.
Stability study: All the concentrations of pirfenidone (30.75,
0.62, and 0.077 mg/l) were stable at room temperature for 24
h. The concentrations of pirfenidone did not deviate from their
original concentrations for more than 10%.
Ocular pharmacokinetics: Pirfenidone concentrations versus
time  profiles  in  various  ocular  tissues  after  topical
administration  are  shown  in  Table  1  and  Figure  2.  The
pharmacokinetic  parameters  are  listed  in  Table  2.  The
concentration of pirfenidone peaked within 20 min among all
the ocular tissues, and the distributions were fast. The Cmax
was 9.64 mg/g, 9.62 mg/g, 34.88 mg/l, 0.52 mg/l, and 2.13 mg/
g  for  cornea,  conjunctiva,  aqueous  humor,  vitreous,  and
sclera, respectively.
DISCUSSION
Pirfenidone has shown its anti-inflammatory and anti-fibrotic
effect in in vitro and in vivo models of pulmonary and renal
fibrosis  [16].  Pirfenidone  has  shown  its  excellent  oral  or
intravenous absorption and its pharmacokinetic behavior has
been studied in mice [20], beagle dog [21], horse [22], sheep
[23],  and  human  [24-26].  In  several  large-scale  phase  III
clinical trials, oral pirfenidone was safe and generally well
tolerated [16,27]. The most frequent side effects included
photosensitivity rash, nausea, dyspepsia, and dizziness [16,
27].
Pirfenidone is known to inhibit a variety of cytokines in
wound healing process. These include TGF-β [28], connective
tissue growth factor (CTGF) [15], platelet-derived growth
factors (PDGF) [29], and tumor necrosis factor-alpha (TNF-
α) [30]. Our group has previously shown that pirfenidone had
inhibiting effect on human Tenon’s fibroblasts and reduced
wound healing response in glaucoma filtering site in rabbit
model [17]. The in vitro study showed that the inhibiting effect
of pirfenidone on human Tenon’s fibroblast started at the
concentration  of  0.15mg/ml  and  went  into  plateau  at  the
concentration of 0.3 mg/ml [17]. Furthermore, both slit-lamp
observation  and  histological  analysis  showed  that  topical
administration of 0.1% and 0.5% pirfenidone had no apparent
toxicity in cornea, ciliary body, and retina, with no apparent
irritation to rabbit eye [18].
In  this  study,  we  characterized  the  pharmacokinetic
profile of 0.5% pirfenidone after its topical administration in
rabbit  eyes.  Pirfenidone  in  ocular  tissues  exhibited  short-
terminal half-lives (18 to 72 min). This rapid turnover is not













2 7.53±0.35 8.87±1.17 1.34±0.05 19.59±7.28 0.30±0.01
5 7.02±0.96 9.14±1.32 1.00±0.53 20.39±6.54 0.47±0.17
8 9.64±0.99 9.62±0.81 2.13±1.02 30.29±9.69 0.50±0.01
10 8.25±0.28 5.63±1.40 0.69±0.35 34.88±11.10 0.36±0.12
15 8.32±1.06 6.43±1.61 1.04±0.34 16.92±1.18 0.51±0.02
20 4.00±1.47 1.46±0.44 0.36±0.13 15.02±6.74 0.14±0.04
30 2.26±1.03 0.98±0.31 0.25±0.16 10.79±3.72 0.12±0.03
60 1.03±0.33 0.73±0.32 0.14±0.10 4.06±2.03 0.08±0.02
90 1.34±0.25 0.57±0.17 0.50±0.09 2.43±0.17 0.05±0.00
120 0.10±0.04 0.19±0.11 0.05±0.03 0.271±0.16 0.05±0.01
SD=standard deviation.
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many other ophthalmic agents such as latanoprost (t1/2 in the
aqueous humor of rabbit=3 h) [31], timolol (t1/2=1.1 h) [32],
and  carteolol  (t1/2=1.5  h)  [33].  Topical  ocular  drug
administration usually allows only a short contact time on the
ocular surface. The duration of drug action may be prolonged
by  formulation  design  (e.g.,  gelifying  formulations,
ointments, inserts).
We were primarily interested in the 0.5% pirfenidone, as
our previous study has shown that this dosage had a significant
effect  in  inhibiting  wound  healing  response  in  glaucoma
filtering site in rabbit model [18]. It should be noted that the
Figure 2. Pirfenidone concentration-time (C-t) profiles in ocular tissues. A-E: The C-t profiles obtained from cornea, conjunctiva, sclera,
aqueous humor, and vitreous, respectively, after topical administration of pirfenidone.
TABLE 2. PHARMACOKINETIC PARAMETERS IN OCULAR TISSUES AFTER TOPICAL ADMINISTRATION OF 0.5% PIRFENIDONE SOLUTION IN RABBIT EYES.
Pharmacokinetic parameters Cornea Conjunctiva Sclera Aqueous humor Vitreous
Tmax (min) 8 8 8 10 15
Cmax (mg/l)* 9.64* 9.62* 2.13* 34.88 0.52
AUC0-t (min•mg/l) 282.03 197.70 46.65 919.84 15.17
AUC0-∞ (min•mg/l) 284.58 206.91 49.34 925.99 19.88
T1/2 (min) 18.26 34.16 39.48 15.71 70.91
Lambda_z (1/min•10–1) 0.38 0.20 0.18 0.44 0.10
        Cmax=observed  maximum  concentration;  Tmax=time  to  Cmax;  AUC0-t=area  under  the  curve  until  the  last  measurable
        concentration; AUC0-∞=area under the curve from 0 to infinity; T1/2=Elimination half-life; and Lambda_z=First order rate
        constant associated with the terminal (log-linear) portion of the curve. *The concentration of pirfenidone in cornea, conjunctiva,
        and sclera is determined as milligrams per gram of tissue.
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2194behavior of pirfenidone in human eyes may differ from that
in rabbit eyes, given that the rabbit vitreous volume is smaller,
and the retina is thinner, than those in human eyes. The uptake
of pirfenidone in the conjunctiva was very quick, with the
concentration  peaking  after  8  min  (9.62  mg/ml)  and
diminishing to 0.19 mg/ml after 2 h. Therefore, if we assume
that the in vitro environment and in vivo condition are similar,
an initial topical administration of 0.5% pirfenidone may have
a 2-h anti-fibrotic effect on glaucoma filtering region.
Given that pirfenidone has a broad spectrum of anti-
fibrotic  effect,  further  studies  are  needed  to  investigate
whether pirfenidone could offer its potential therapeutic effect
in  fibrosis-related  ocular  diseases  such  as  proliferative
diabetic  retinopathy  and  corneal  wound  healing  response.
These are currently under planning. Our study showed that
pirfenidone could be internalized into conjunctiva, aqueous
humor,  vitreous,  and  sclera,  in  addition  to  cornea.  The
concentration of pirfenidone in vitreous was lower than in the
cornea, but the concentration in aqueous humor was fourfold
at 8 min and threefold at 120 min higher than in cornea. If
pirfenidone is useful for the modulation of corneal wound
response  and  proliferative  diabetic  retinopathy,  it  would
become  necessary  to  characterize  its  ocular  concentration
after subconjunctival and intravitreal administration.
In  summary,  we  show  that  topical  application  of
pirfenidone should be studied further as a modulating method
for wound healing response after glaucoma filtering surgery.
Measurable  concentrations  of  pirfenidone  are  achieved  in
various ocular tissues. Formulation design may be needed to
prolong the duration of drug action. Because of its broad
spectrum  of  activity,  pirfenidone  has  a  potential  for  the
modulation of other ocular wound healing responses as well.
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